palliative endocrinology
Osteoporosis Risk Assessment Instrument (ORAI)
3-item clinical screening tool to identify postmenopausal women at risk of low bone mineral density (BMD) who should be referred for DEXA scanning. Considers age, weight, and oestrogen use. Score ≥9 = refer for DEXA.
References
- Cadarette SM et al. Development and validation of the Osteoporosis Risk Assessment Instrument to facilitate selection of women for bone densitometry. CMAJ. 2000;162(9):1289–1294.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Denosumab · Anti-RANKL Monoclonal Antibody
- Denosumab · RANK Ligand Inhibitor (Anti-resorptive)
- Alendronic Acid (Alendronate) · Bisphosphonate (bone resorption inhibitor)
- Zoledronic Acid · IV Bisphosphonate
- Ciprofloxacin with dexamethasone · Topical otic antibiotic + corticosteroid
- Zoledronic Acid · Bisphosphonate
Pathways
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
- Adult Hypoglycaemia (Treated Diabetes) · JBDS-IP (2023): Hospital Management of Hypoglycaemia
- Adrenal Crisis · Society for Endocrinology Emergency Guidance (2024)
- Type 2 Diabetes Management · NICE NG28 2022
- Hyperthyroidism Management · BTA / ETA 2018
- Adrenal Insufficiency · Society of Endocrinology / ESE 2016
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.